Fortress Biotech
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 186
- Market Cap
- $46.7M
- Introduction
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
Fortress Biotech Reports Strong 2024 Results with Two FDA Approvals and Strategic Acquisition Deal
Fortress Biotech secured FDA approvals for two key products in Q4 2024: Emrosi for inflammatory lesions of rosacea and UNLOXCYT for advanced cutaneous squamous cell carcinoma, with commercial launch of Emrosi already underway.
Fortress Biotech and Partex Form Strategic AI Partnership to Accelerate Drug Discovery and Development
Fortress Biotech and Partex NV have announced a strategic collaboration leveraging Partex's proprietary AI platform to identify and evaluate biopharmaceutical compounds for potential acquisition or licensing.
Sun Pharma to Acquire Checkpoint Therapeutics in $355 Million Deal for Novel Skin Cancer Treatment
Sun Pharmaceutical Industries will acquire Checkpoint Therapeutics for $355 million upfront, with stockholders receiving $4.10 per share plus a contingent value right worth up to $0.70 per share based on European approval milestones.
Fortress Biotech's Triplex Enters Phase 2 Trial for CMV Prevention in Stem Cell Transplant Recipients
Fortress Biotech and Helocyte have dosed the first subject in a Phase 2 trial of Triplex, a CMV vaccine, for stem cell transplant recipients.
FDA Grants Priority Review to CUTX-101 for Menkes Disease, Offering Hope for Rare Pediatric Condition
The FDA has accepted Sentynl Therapeutics' NDA for CUTX-101, granting priority review for the treatment of Menkes disease, a rare genetic disorder.
Fortress Biotech's Emrosi Receives FDA Approval for Rosacea Treatment
The FDA approved Emrosi (minocycline hydrochloride extended-release capsules, 40mg) for treating inflammatory lesions of rosacea in adults, marking Fortress Biotech's first FDA approval.
Fortress Biotech Highlights FDA Approval of Emrosi and Cosibelimab's Upcoming PDUFA Date
Fortress Biotech announced FDA approval for Emrosi (minocycline hydrochloride) for treating inflammatory lesions of rosacea in adults, marking their first FDA approval.